ARNA » Topics » Our Strategy

These excerpts taken from the ARNA 10-K filed Mar 16, 2009.

Our Strategy

The key elements of our general scientific and business strategy are as follows:

 

   

Advance our lead candidates. We intend to selectively advance our current drug candidates, with a partner or independently, through clinical development and, if successful, to commercialization.

 

   

Discover and develop additional drug candidates targeting GPCRs. We intend to continue to discover and develop oral, small molecule compounds for GPCRs identified or validated through our research efforts.

 

   

Focus on attractive market opportunities. Obesity, diabetes, atherosclerosis and arterial thrombosis each represent large market opportunities. We intend to continue to focus on these and other markets with attractive commercial potential.

 

   

Recognize significant economic value for our drug candidates. We intend to maximize the value of our drug candidates through both independent development and licensing and other partnership opportunities.

 

   

Improve and develop our capabilities. To capitalize on our discoveries, we plan to selectively improve and develop our capabilities as our drug candidates enter into, and move through, clinical trials and to commercialization.

 

   

Maintain strong discovery research capabilities. Our technologies, our drug discovery infrastructure and the integrated approach to research used by our scientists have allowed us to identify a number of GPCR targets and novel compounds. We believe these and other discoveries will fuel our pipeline for future development.

Our Strategy

The key
elements of our general scientific and business strategy are as follows:

 







  

Advance our lead candidates. We intend to selectively advance our current drug candidates, with a partner or independently, through clinical
development and, if successful, to commercialization.

 







  

Discover and develop additional drug candidates targeting GPCRs. We intend to continue to discover and develop oral, small molecule
compounds for GPCRs identified or validated through our research efforts.

 







  

Focus on attractive market opportunities. Obesity, diabetes, atherosclerosis and arterial thrombosis each represent large market opportunities.
We intend to continue to focus on these and other markets with attractive commercial potential.

 







  

Recognize significant economic value for our drug candidates. We intend to maximize the value of our drug candidates through both independent
development and licensing and other partnership opportunities.

 







  

Improve and develop our capabilities. To capitalize on our discoveries, we plan to selectively improve and develop our capabilities as our drug
candidates enter into, and move through, clinical trials and to commercialization.

 







  

Maintain strong discovery research capabilities. Our technologies, our drug discovery infrastructure and the integrated approach to research used
by our scientists have allowed us to identify a number of GPCR targets and novel compounds. We believe these and other discoveries will fuel our pipeline for future development.

STYLE="margin-top:18px;margin-bottom:0px">Intellectual Property

Our success depends in large
part on our ability to protect our proprietary technologies, compounds and information, and to operate without infringing the proprietary rights of third parties. We rely on a combination of patent, trade secret, copyright, and trademark laws, as
well as confidentiality, licensing and other agreements, to establish and protect our proprietary rights. We seek patent protection for our key inventions, including drug candidates we identify, routes for chemical synthesis, pharmaceutical
formulations and drug screening technologies.

As of January 31, 2009, we owned, in part or in whole, or had exclusively licensed the
following patents: 28 in the United States, 7 in Japan, 14 in Germany, 14 in France, 14 in the United Kingdom, 14 in Italy, 14 in Spain, 2 in Canada, 3 in China, and approximately 503 in other jurisdictions. In addition, as of January 31, 2009,
we had approximately 1,310 patent applications before the United States Patent and Trademark Office, foreign patent offices and international patent authorities. These patents and patent applications are divided into 118 distinct families of related
patents that are directed to chemical compositions of matter, methods of treatment using chemical compositions, GPCR genes, CART, Melanophore technology, or other novel screening methods. One of our patent families was exclusively in-licensed
and contains a single issued patent. One hundred and nine of our patent families, which include a total of about 530 patents and 1,219 patent applications, were invented solely by our employees. The remaining 8 of our patent families, which include
a total of about 82 patents and 91 patent applications, were the subject of joint inventions by our employees and the employees of other entities. There is

 


13







Table of Contents



no assurance that any of our patent applications will issue, or that any of the patents will be enforceable or will cover a drug or other commercially
significant product or method. Except for the US patents relating to our Melanophore technology, the term of most of our other current patents commenced, and most of our future patents, if any, will commence, on the date of issuance and terminate
20 years from the earliest effective filing date of the patent application. Since our US Melanophore patents were issued under now superseded rules that provided a patent term of 17 years from the date of issuance, the term of these
patents is scheduled to end in 2012. Because the time from filing a patent application relating to our business to the issuance, if ever, of the patent is often more than three years and because any marketing and regulatory approval for a drug often
occurs several years after the related patent application is filed, the resulting market exclusivity afforded by any patent on our drug candidates and technologies may be substantially less than 20 years. In the United States, the European
Union and some other jurisdictions, patent term extensions are available for certain delays in either patent office proceedings or marketing and regulatory approval processes. However, due to the specific requirements for obtaining these extensions,
there is no assurance that our patents will be afforded extensions even if we encounter significant delays in patent office proceedings or marketing and regulatory approval.

STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%">In addition to patent protection, we rely on trade secrets, proprietary know-how, and continuing technological advances to develop and maintain our
competitive position. To maintain the confidentiality of our trade secrets and proprietary information, all of our employees are required to enter into and adhere to an employee confidentiality and invention assignment agreement, laboratory notebook
policy, and invention disclosure procedures as a condition of employment. Additionally, our employee confidentiality and invention assignment agreements require that our employees not bring to us, or use without proper authorization, any third-party
proprietary technology. We also require our consultants and collaborators that have access to proprietary property and information to execute confidentiality and invention rights agreements in our favor before beginning their relationship with us.
While such arrangements are intended to enable us to better control the use and disclosure of our proprietary property and provide for our ownership of proprietary technology developed on our behalf, they may not provide us with meaningful
protection for such property and technology in the event of unauthorized use or disclosure.

These excerpts taken from the ARNA 10-K filed Mar 5, 2008.

Our Strategy

        The key elements of our scientific and business strategy are to:

    Advance our lead programs.  We intend to continue to advance our current drug candidates, with a partner or independently, through clinical development and, if successful, to commercialization.

    Discover and develop additional small molecule drug candidates targeting GPCRs.  We intend to continue to discover and develop oral, small molecule compounds for GPCRs identified or validated through our research efforts.

15


    Focus on attractive market opportunities.  Obesity, insomnia, diabetes, atherosclerosis and arterial thrombosis each represent large market opportunities. We intend to continue to focus on these and other markets with attractive commercial potential.

    Recognize significant economic value for our drug candidates under development.  We intend to maximize the value of our drug candidates through both independent development and licensing and other partnership opportunities with pharmaceutical and larger biotechnology companies.

    Continue to build our capabilities.  To capitalize on our discoveries, we plan to continue to improve and expand our capabilities as our drug candidates enter into, and move through, clinical trials and to commercialization.

    Maintain strong discovery research capabilities.  Our proprietary technologies, our drug discovery infrastructure and the integrated approach to research used by our scientists, have allowed us to identify a number of GPCR targets and novel compounds. We believe these and other discoveries will continue to fuel our pipeline.

Our Strategy



        The key elements of our scientific and business strategy are to:





    Advance our lead programs.  We intend to continue to advance our current drug candidates,
    with a partner or independently, through clinical development and, if successful, to commercialization.


    Discover and develop additional small molecule drug candidates
    targeting GPCRs.
      We intend to continue to discover and develop oral, small molecule compounds for GPCRs identified or validated through our research
    efforts.


15












    Focus on attractive market opportunities.  Obesity, insomnia, diabetes, atherosclerosis
    and arterial thrombosis each represent large market opportunities. We intend to continue to focus on these and other markets with attractive commercial potential.


    Recognize significant economic value for our drug candidates under development.  We
    intend to maximize the value of our drug candidates through both independent development and licensing and other partnership opportunities with pharmaceutical and larger biotechnology companies.


    Continue to build our capabilities.  To capitalize on our discoveries, we plan to
    continue to improve and expand our capabilities as our drug candidates enter into, and move through, clinical trials and to commercialization.


    Maintain strong discovery research capabilities.  Our proprietary technologies, our drug
    discovery infrastructure and the integrated approach to research used by our scientists, have allowed us
    to identify a number of GPCR targets and novel compounds. We believe these and other discoveries will continue to fuel our pipeline.



This excerpt taken from the ARNA 10-K filed Mar 6, 2007.

Our Strategy

The key elements of our scientific and business strategy are to:

·                  Advance our lead programs. We intend to continue to advance our current drug candidates, with a partner or independently, through clinical development and, if successful, to commercialization.

·                  Discover and develop additional small molecule drug candidates targeting GPCRs. We intend to continue to discover and develop orally bio-available, small molecule compounds for GPCRs identified or validated through our research efforts.

·                  Focus on attractive market opportunities. Obesity, insomnia, diabetes, atherosclerosis and arterial thrombosis each represent large market opportunities. We intend to continue to focus on these and other markets with attractive commercial potential.

·                  Recognize significant economic value for our drug candidates under development. We intend to maximize the value of our drug candidates through both independent development and licensing and other partnership opportunities with pharmaceutical and larger biotechnology companies.

·                  Continue to build our development capabilities. To capitalize on our discoveries, we plan to continue to expand our clinical development capabilities as our drug candidates enter into, and move through, clinical trials.

·                  Maintain strong discovery research capabilities. Our proprietary technologies, our drug discovery infrastructure and the integrated approach to research used by our scientists, have allowed us to identify a number of GPCR targets and novel compounds. We believe these and other discoveries will continue to fuel our pipeline.

This excerpt taken from the ARNA 10-K filed Mar 7, 2006.

Our Strategy

 

The key elements of our scientific and business strategy are to:

 

                  Advance our lead programs.    We intend to continue to advance our current drug candidates, with a partner or independently, through clinical development and, if successful, to commercialization.

 

                  Discover and develop additional small molecule drug candidates targeting GPCRs.    We intend to continue to discover and develop orally bio-available, small-molecule compounds for GPCRs identified or validated through our research efforts.

 

                  Focus on attractive market opportunities.    Obesity, insomnia, diabetes, atherosclerosis and arterial thrombosis each represent multi-billion dollar market opportunities. We intend to continue to focus on these and other markets with attractive commercial potential.

 

                  Retain significant commercial rights and/or economic value for our drug candidates.    We intend to maximize the value of our drug candidates through both independent development and partnerships with pharmaceutical and larger biotechnology companies with commercial infrastructures.

 

                  Continue to build our development capabilities.    To capitalize on our discoveries, we plan to continue to expand our clinical development capabilities as our drug candidates enter into, and move through, clinical trials.

 

                  Maintain strong discovery research capabilities.    Our proprietary technologies, our drug discovery infrastructure and the integrated approach to research used by our scientists, have allowed us to identify a number of GPCR targets and novel compounds. We believe these and other discoveries will continue to fuel our pipeline.

 

This excerpt taken from the ARNA 10-K filed Mar 2, 2005.

Our Strategy

 

The key elements of our scientific and business strategy are to:

 

Continue to advance our lead programs.  We intend to advance our current product candidates, either alone or in conjunction with pharmaceutical and biotechnology companies, through clinical development and, if successful, commercialization.

 

Discover and develop additional small molecule product candidates targeting GPCRs.  We intend to continue to develop orally available, small molecule compounds for GPCRs identified or validated by our research efforts.

 

Focus on attractive market opportunities.  Obesity, insomnia, diabetes and thrombosis each represent multi-billion dollar market opportunities. We intend to continue to focus on these and other programs with attractive commercial potential.

 

Retain significant commercial rights and/or economic value for our product candidates.  We intend to maximize the value of our product candidates through either internal development or commercial partnerships in which we retain significant economic value and/or targeted copromotion rights.

 

Continue to build our development capabilities.  To capitalize on our discoveries, we plan to continue to expand our clinical development capabilities as our product candidates enter into, and move through, clinical trials.

 

Maintain strong research discovery capabilities.  Our proprietary technologies, including CART and Melanophore, and our drug discovery infrastructure, have allowed us to identify a number of GPCR targets and novel compounds. We believe these and other discoveries will continue to fuel our pipeline.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki